Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMELLIA: Metronomic vs Intermittent Capecitabine Maintenance in HER2- mBC
NCT01917279Phase 3Unknown
- Sponsor
- Binghe Xu
- Start
- Oct 2013
- Primary completion
- Jul 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in breast cancer, sponsored by Binghe Xu. Status: unknown.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01917279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01917279.